Abstract
The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.
Author supplied keywords
Cite
CITATION STYLE
Genge, A., Cedarbaum, J. M., Shefner, J., Chio, A., Al-Chalabi, A., Van Damme, P., … van den Berg, L. H. (2024). The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25(3–4), 382–387. https://doi.org/10.1080/21678421.2024.2320880
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.